{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:03:42Z","timestamp":1793811822989,"version":"4.6.1"},"reference-count":211,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials Advances"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bioadv.2024.214120","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T13:56:34Z","timestamp":1732024594000},"page":"214120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["siRNA-based nanotherapeutic approaches for targeted delivery in rheumatoid arthritis"],"prefix":"10.1016","volume":"168","author":[{"given":"Sweta","family":"Sawan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Majie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varnita","family":"Karmakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimmy","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santanu","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bapi","family":"Gorain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioadv.2024.214120_bb0005","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"Abbafati","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bioadv.2024.214120_bb0010","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/rheumatology\/ket414","article-title":"Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets","volume":"53","author":"Furst","year":"2014","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1016\/j.bioadv.2024.214120_bb0015","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/13543776.18.7.723","article-title":"The development of novel therapies for rheumatoid arthritis","volume":"18","author":"Quan","year":"2008","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioadv.2024.214120_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells7100161","article-title":"Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development","volume":"7","author":"Yap","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.bioadv.2024.214120_bb0025","first-page":"172","article-title":"Innate immunity drives pathogenesis of rheumatoid arthritis","volume":"44","author":"Edilova","year":"2021","journal-title":"Biom. J."},{"key":"10.1016\/j.bioadv.2024.214120_bb0030","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1476-5381.2010.01099.x","article-title":"Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors","volume":"162","author":"Mewar","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0035","first-page":"1","article-title":"Emerging therapies in rheumatoid arthritis","volume":"F1000Res 8","author":"Senolt","year":"2019","journal-title":"Focus on monoclonal antibodies."},{"key":"10.1016\/j.bioadv.2024.214120_bb0040","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ymthe.2021.01.013","article-title":"Three decades of clinical gene therapy: from experimental technologies to viable treatments","volume":"29","author":"Tremblay","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioadv.2024.214120_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2019.107502","article-title":"The approved gene therapy drugs worldwide: from 1998 to 2019","volume":"40","author":"Ma","year":"2020","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.bioadv.2024.214120_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3015","article-title":"Gene therapy clinical trials worldwide to 2017: an update","volume":"20","author":"Ginn","year":"2018","journal-title":"J. Gene Med."},{"key":"10.1016\/j.bioadv.2024.214120_bb0055","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41584-018-0009-5","article-title":"Arthritis gene therapy is becoming a reality","volume":"14","author":"Evans","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0060","first-page":"139","article-title":"Viral vectors in gene therapy","volume":"103","author":"Slade","year":"2001","journal-title":"Period. Biol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0065","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.tibtech.2018.08.010","article-title":"Non-viral delivery to enable genome editing","volume":"37","author":"Rui","year":"2019","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0070","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","article-title":"FDA-approved oligonucleotide therapies in 2017","volume":"25","author":"Stein","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioadv.2024.214120_bb0075","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"issue":"482","key":"10.1016\/j.bioadv.2024.214120_bb0080","first-page":"7385","volume":"16","year":"2012","journal-title":"Regulatory rna"},{"key":"10.1016\/j.bioadv.2024.214120_bb0085","doi-asserted-by":"crossref","first-page":"17372","DOI":"10.1073\/pnas.1114465108","article-title":"Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage","volume":"108","author":"Shi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioadv.2024.214120_bb0090","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/annrheumdis-2014-206785","article-title":"Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis","volume":"75","author":"Juarez","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bioadv.2024.214120_bb0095","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.24827","article-title":"Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis","volume":"61","author":"Aggarwal","year":"2009","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.bioadv.2024.214120_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res."},{"key":"10.1016\/j.bioadv.2024.214120_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antib8020037","article-title":"Specificity of anti-Citrullinated protein antibodies in rheumatoid arthritis","volume":"8","author":"Trier","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.bioadv.2024.214120_bb0110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41392-023-01331-9","article-title":"Signaling pathways in rheumatoid arthritis: implications for targeted therapy","volume":"8","author":"Ding","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioadv.2024.214120_bb0115","doi-asserted-by":"crossref","first-page":"6651","DOI":"10.1038\/ncomms7651","article-title":"Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss","volume":"6","author":"Harre","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioadv.2024.214120_bb0120","doi-asserted-by":"crossref","first-page":"11133","DOI":"10.1073\/pnas.1208669109","article-title":"Quantitative assessment of the impact of the gut microbiota on lysine \u03b5-acetylation of host proteins using gnotobiotic mice","volume":"109","author":"Simon","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioadv.2024.214120_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1759720X211022533","article-title":"Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis","volume":"13","author":"Studenic","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.bioadv.2024.214120_bb0130","first-page":"1","article-title":"Anti-citrullinated protein antibodies in patients with rheumatoid arthritis: biological effects and mechanisms of immunopathogenesis","volume":"21","author":"Wu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioadv.2024.214120_bb0135","doi-asserted-by":"crossref","first-page":"934","DOI":"10.15537\/smj.2017.9.20841","article-title":"Anti-carbamylated protein antibodies in rheumatoid arthritis patients and their association with rheumatoid factor","volume":"38","author":"Othman","year":"2017","journal-title":"Saudi Med. J."},{"key":"10.1016\/j.bioadv.2024.214120_bb0140","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.autrev.2013.10.008","article-title":"Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies","volume":"13","author":"Shi","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"2010","key":"10.1016\/j.bioadv.2024.214120_bb0145","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bioadv.2024.214120_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1759720X21989868","article-title":"The value of anti-CarP and anti-PAD4 as markers of rheumatoid arthritis in ACPA\/RF negative rheumatoid arthritis patients","volume":"13","author":"Kolarz","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.bioadv.2024.214120_bb0155","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1136\/annrheumdis-2013-205109","article-title":"Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies","volume":"73","author":"Jiang","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bioadv.2024.214120_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010922","article-title":"Cytokine networks in the pathogenesis of rheumatoid arthritis","volume":"22","author":"Kondo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioadv.2024.214120_bb0165","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1302\/2046-3758.117.BJR-2021-0594.R1","article-title":"Immunomodulatory role of T helper cells in rheumatoid arthritis: a COMPREHENSIVE RESEARCH REVIEW","volume":"11","author":"Luo","year":"2022","journal-title":"Bone Joint Res."},{"key":"10.1016\/j.bioadv.2024.214120_bb0170","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bioadv.2024.214120_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mmr.2022.12615","article-title":"Cartilage tissue engineering: from proinflammatory and anti-inflammatory cytokines to osteoarthritis treatments (review)","volume":"25","author":"Liu","year":"2022","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bioadv.2024.214120_bb0180","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2474-11-61","article-title":"Expression and regulation of HIF-1alpha in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor","volume":"11","author":"Westra","year":"2010","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.bioadv.2024.214120_bb0185","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/cells9040880","article-title":"Update on the Pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bioadv.2024.214120_bb0190","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bioadv.2024.214120_bb0195","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor \u03b1 therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bioadv.2024.214120_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/B:PHAM.0000012145.49054.6c","article-title":"Pharmaceutical prospects for RNA interference","volume":"21","author":"Schiffelers","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioadv.2024.214120_bb0205","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.1072457","article-title":"Zamore, ancient pathways programmed by small RNAs","volume":"296","author":"Philip","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bioadv.2024.214120_bb0210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10555-017-9717-6","article-title":"RNA interference-based therapy and its delivery systems","volume":"37","author":"Chen","year":"2018","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bioadv.2024.214120_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2019.07.002","article-title":"Applications of RNA interference in the treatment of arthritis","volume":"214","author":"Rai","year":"2019","journal-title":"Transl. Res."},{"key":"10.1016\/j.bioadv.2024.214120_bb0220","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.3390\/pharmaceutics14112520","article-title":"siRNA functionalized lipid nanoparticles (LNPs) in Management of Diseases","volume":"14","author":"Kalita","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioadv.2024.214120_bb0225","article-title":"The emerging potential of siRNA nanotherapeutics in treatment of arthritis","volume":"18","author":"Kumari","year":"2023","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.bioadv.2024.214120_bb0230","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cell.2004.06.017","article-title":"Single processing center models for human dicer and bacterial RNase III","volume":"118","author":"Zhang","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.bioadv.2024.214120_bb0235","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2016.04.009","article-title":"Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer","volume":"164","author":"Wigerup","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioadv.2024.214120_bb0240","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1471-2474-12-261","article-title":"Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study","volume":"12","author":"Haraoui","year":"2011","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.bioadv.2024.214120_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001881","article-title":"Hypoxia-inducible factor-2\u03b1 is an essential catabolic regulator of inflammatory rheumatoid arthritis","volume":"12","author":"Ryu","year":"2014","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030275","article-title":"Systematic review and Meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis","volume":"7","author":"Aaltonen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bioadv.2024.214120_bb0255","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/annrheumdis-2014-eular.4257","article-title":"OP0296 hypoxia-inducible factor 2A regulates macrophage function in rheumatoid arthritis","volume":"73","author":"Hardy","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bioadv.2024.214120_bb0260","doi-asserted-by":"crossref","first-page":"75i","DOI":"10.1136\/ard.59.suppl_1.i75","article-title":"Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha","volume":"59","author":"Williams","year":"2000","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bioadv.2024.214120_bb0265","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/rheumatology\/keg327","article-title":"Pathogenesis of bone and cartilage destruction in rheumatoid arthritis","volume":"42","author":"Goldring","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.bioadv.2024.214120_bb0270","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/ar2292","article-title":"Cells of the synovium in rheumatoid arthritis","volume":"9","author":"Otero","year":"2007","journal-title":"Chondrocytes, Arthritis Res. Ther."},{"key":"10.1016\/j.bioadv.2024.214120_bb0275","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s10067-007-0605-2","article-title":"Synovial proliferation differentially affects hypoxia in the joint cavities of rheumatoid arthritis and osteoarthritis patients","volume":"26","author":"Lee","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0280","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrrheum.2011.205","article-title":"Hypoxia\u2014a key regulator of angiogenesis and inflammation in rheumatoid arthritis","volume":"8","author":"Konisti","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0285","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/rb\/rbw010","article-title":"Calcium phosphate nanoparticles-based systems for siRNA delivery","volume":"3","author":"Xu","year":"2016","journal-title":"Regen. Biomater."},{"key":"10.1016\/j.bioadv.2024.214120_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.579266","article-title":"Non-transcriptional and translational function of canonical NF-\u03baB signaling in activating ERK1\/2 in IL-1\u03b2-induced COX-2 expression in synovial fibroblasts","volume":"11","author":"Nakano","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0295","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","article-title":"The pathogenesis of rheumatoid arthritis","volume":"55","author":"Alivernini","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.bioadv.2024.214120_bb0300","doi-asserted-by":"crossref","unstructured":"Z. Szekanecz, A.E. Koch, Vascular involvement in rheumatic diseases: \u201cvascular rheumatology,\u201d Arthritis Res. Ther. 10 (2008) 224. doi:https:\/\/doi.org\/10.1186\/ar2515.","DOI":"10.1186\/ar2515"},{"key":"10.1016\/j.bioadv.2024.214120_bb0305","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/01.bor.0000155361.83990.5b","article-title":"Hypoxia and angiogenesis in rheumatoid arthritis","volume":"17","author":"Taylor","year":"2005","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0310","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11420-007-9072-1","article-title":"Role of Wnt signaling in bone remodeling and repair","volume":"4","author":"Issack","year":"2008","journal-title":"HSS J."},{"key":"10.1016\/j.bioadv.2024.214120_bb0315","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood-2008-03-145169","article-title":"The role of Dickkopf-1 in bone development, homeostasis, and disease","volume":"113","author":"Pinzone","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bioadv.2024.214120_bb0320","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1534-5807(03)00266-1","article-title":"A second canon","volume":"5","author":"Veeman","year":"2003","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bioadv.2024.214120_bb0325","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/art.10593","article-title":"Regulation of fibronectin and metalloproteinase expression by Wnt signaling in rheumatoid arthritis synoviocytes","volume":"46","author":"Sen","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bioadv.2024.214120_bb0330","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1534\/genetics.105.045245","article-title":"Genetic evidence that Drosophila frizzled controls planar cell polarity and Armadillo signaling by a common mechanism","volume":"171","author":"Povelones","year":"2005","journal-title":"Genetics"},{"key":"10.1016\/j.bioadv.2024.214120_bb0335","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/ncprheum0881","article-title":"The role of Wnt proteins in arthritis","volume":"4","author":"Schett","year":"2008","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0340","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/BOR.0b013e32816e06f9","article-title":"The Wnt signaling pathway and bone metabolism","volume":"19","author":"Johnson","year":"2007","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0345","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioadv.2024.214120_bb0350","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10787-022-00974-4","article-title":"Elucidating the role of hypoxia-inducible factor in rheumatoid arthritis","volume":"30","author":"Sabi","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.bioadv.2024.214120_bb0355","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.ymthe.2019.05.002","article-title":"Lipidoid-siRNA nanoparticle-mediated IL-1\u03b2 gene silencing for systemic arthritis therapy in a mouse model","volume":"27","author":"Song","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioadv.2024.214120_bb0360","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s002770050308","article-title":"The role of cytokines and hematopoietic growth factors in the autocrine\/paracrine regulation of inducible hematopoiesis","volume":"75","author":"Cluitmans","year":"1997","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0365","first-page":"991","article-title":"Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells","volume":"138","author":"Zoja","year":"1991","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0370","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3950\/jibiinkoka.103.829","article-title":"IL-1 and TNF-.ALPHA.-mediated regulation of IL-6, IL-8 and GM-CSF release from cultured nasal epithelial cells","volume":"103","author":"Yamagishi","year":"2000","journal-title":"Nippon Jibiinkoka Gakkai Kaiho"},{"key":"10.1016\/j.bioadv.2024.214120_bb0375","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cca.2016.02.010","article-title":"Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis","volume":"455","author":"Mateen","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bioadv.2024.214120_bb0380","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/rheumatology\/41.3.329","article-title":"The role of TNF-\u03b1 in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA\/SCID mouse chimera","volume":"41","author":"Matsuno","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.bioadv.2024.214120_bb0385","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jconrel.2018.05.035","article-title":"Lipid nanoparticles with minimum burst release of TNF-\u03b1 siRNA show strong activity against rheumatoid arthritis unresponsive to methotrexate","volume":"283","author":"Aldayel","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2024.214120_bb0390","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/mt.2013.245","article-title":"TNF-\u03b1 gene silencing using polymerized siRNA\/Thiolated glycol chitosan nanoparticles for rheumatoid arthritis","volume":"22","author":"Lee","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioadv.2024.214120_bb0395","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/mt.2008.220","article-title":"Chitosan\/siRNA nanoparticle\u2013mediated TNF-\u03b1 knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model","volume":"17","author":"Howard","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioadv.2024.214120_bb0400","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/vetsci9100531","article-title":"Effect and mechanism of siRNAs targeting IL-1\u03b2\/TNF-\u03b1 combined with BMSCs transplantation in ameliorating rheumatoid arthritis in rats","volume":"9","author":"Pan","year":"2022","journal-title":"Vet. Sci."},{"key":"10.1016\/j.bioadv.2024.214120_bb0405","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ejpb.2012.07.021","article-title":"PLGA microspheres encapsulating siRNA anti-TNFalpha: efficient RNAi-mediated treatment of arthritic joints","volume":"82","author":"Pr\u00e9sumey","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.bioadv.2024.214120_bb0410","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3389\/fimmu.2020.01668","article-title":"Hypoxia-inducible factor is critical for pathogenesis and regulation of immune cell functions in rheumatoid arthritis","volume":"11","author":"Guo","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0415","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/art.41748","article-title":"Notch-1 and Notch-3 mediate hypoxia-induced activation of synovial fibroblasts in rheumatoid arthritis","volume":"73","author":"Chen","year":"2021","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bioadv.2024.214120_bb0420","first-page":"RA89","article-title":"Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis","volume":"10","author":"Jo\u015bko","year":"2004","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.bioadv.2024.214120_bb0425","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13075-015-0816-x","article-title":"HIF-2\u03b1-induced chemokines stimulate motility of fibroblast-like synoviocytes and chondrocytes into the cartilage-pannus interface in experimental rheumatoid arthritis mouse models","volume":"17","author":"Huh","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bioadv.2024.214120_bb0430","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/gt.2015.16","article-title":"Intra-articular delivery of anti-Hif-2\u03b1 siRNA by chondrocyte-homing nanoparticles to prevent cartilage degeneration in arthritic mice","volume":"22","author":"Pi","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.bioadv.2024.214120_bb0435","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jconrel.2022.01.029","article-title":"CaP-based anti-inflammatory HIF-1\u03b1 siRNA-encapsulating nanoparticle for rheumatoid arthritis therapy","volume":"343","author":"Liu","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2024.214120_bb0440","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12951-022-01758-2","article-title":"A pH-responsive metal-organic framework for the co-delivery of HIF-2\u03b1 siRNA and curcumin for enhanced therapy of osteoarthritis","volume":"21","author":"Zhang","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0445","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12929-016-0281-0","article-title":"Hypoxia and its implications in rheumatoid arthritis","volume":"23","author":"Qui\u00f1onez-Flores","year":"2016","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.bioadv.2024.214120_bb0450","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/gt.2015.16","article-title":"Intra-articular delivery of anti-Hif-2\u03b1 siRNA by chondrocyte-homing nanoparticles to prevent cartilage degeneration in arthritic mice","volume":"22","author":"Pi","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.bioadv.2024.214120_bb0455","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cell.2009.03.045","article-title":"The canonical notch signaling pathway: unfolding the activation mechanism","volume":"137","author":"Kopan","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.bioadv.2024.214120_bb0460","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/art.24568","article-title":"Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis","volume":"60","author":"Shen","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bioadv.2024.214120_bb0465","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/cells9010111","article-title":"The role of notch signaling in macrophages during inflammation and infection: implication in rheumatoid arthritis?","volume":"9","author":"Keewan","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bioadv.2024.214120_bb0470","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jconrel.2015.08.025","article-title":"Notch1 targeting siRNA delivery nanoparticles for rheumatoid arthritis therapy","volume":"216","author":"Kim","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2024.214120_bb0475","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11095-018-2401-x","article-title":"Notch-1 siRNA and methotrexate towards a multifunctional approach in Rhematoid arthritis management: a nanomedicine approach","volume":"35","author":"Zhao","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioadv.2024.214120_bb0480","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/art.34397","article-title":"Notch-1 mediates hypoxia-induced angiogenesis in rheumatoid arthritis","volume":"64","author":"Gao","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bioadv.2024.214120_bb0485","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12951-023-02044-5","article-title":"Emerging non-viral vectors for gene delivery","volume":"21","author":"Wang","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0490","first-page":"78","article-title":"Non-viral vectors in gene therapy: recent development","volume":"23","author":"Zu","year":"2021","journal-title":"Challenges, and Prospects, AAPS J"},{"key":"10.1016\/j.bioadv.2024.214120_bb0495","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1021\/acs.molpharmaceut.7b00320","article-title":"Chitosan\/hyaluronic acid nanoparticles: rational design revisited for RNA delivery","volume":"14","author":"Lallana","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioadv.2024.214120_bb0500","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1021\/mp400633r","article-title":"Hexanoic acid and polyethylene glycol double grafted amphiphilic chitosan for enhanced gene delivery: influence of hydrophobic and hydrophilic substitution degree","volume":"11","author":"Layek","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioadv.2024.214120_bb0505","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1021\/nn203745n","article-title":"In vivo sustained release of siRNA from solid lipid nanoparticles","volume":"5","author":"Lobovkina","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.bioadv.2024.214120_bb0510","doi-asserted-by":"crossref","first-page":"32006","DOI":"10.1021\/acsami.8b12393","article-title":"Hyaluronan reduces cationic liposome-induced toxicity and enhances the antitumor effect of targeted gene delivery in mice","volume":"10","author":"Qian","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bioadv.2024.214120_bb0515","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.cej.2019.05.023","article-title":"Dendrimer functionalized carbon quantum dot for selective detection of breast cancer and gene therapy","volume":"373","author":"Ghosh","year":"2019","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.bioadv.2024.214120_bb0520","doi-asserted-by":"crossref","unstructured":"S.B. Hartono, W. Gu, F. Kleitz, J. Liu, L. He, A.P.J. Middelberg, C. Yu, G.Q. (Max) Lu, S.Z. Qiao, Poly- <scp>l<\/scp> -lysine Functionalized Large Pore Cubic Mesostructured Silica Nanoparticles as Biocompatible Carriers for Gene Delivery, ACS Nano 6 (2012) 2104\u20132117. doi:https:\/\/doi.org\/10.1021\/nn2039643.","DOI":"10.1021\/nn2039643"},{"key":"10.1016\/j.bioadv.2024.214120_bb0525","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1021\/acsbiomaterials.0c00014","article-title":"Ultrasound responsive magnetic mesoporous silica nanoparticle-loaded microbubbles for efficient gene delivery","volume":"6","author":"Du","year":"2020","journal-title":"ACS Biomater Sci. Eng."},{"key":"10.1016\/j.bioadv.2024.214120_bb0530","doi-asserted-by":"crossref","unstructured":"Z. Wang, C. Tang, M. Huang, X. Rong, H. Lin, R. Su, Y. Wang, W. Qi, One-Step Synthesis of Peptide\u2013Gold Nanoclusters with Tunable Fluorescence and Enhanced Gene Delivery Efficiency, Langmuir 38 (2022) 14799\u201314807. doi:https:\/\/doi.org\/10.1021\/acs.langmuir.2c02465.","DOI":"10.1021\/acs.langmuir.2c02465"},{"key":"10.1016\/j.bioadv.2024.214120_bb0535","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1021\/am508760w","article-title":"RGD peptide-modified dendrimer-entrapped gold nanoparticles enable highly efficient and specific gene delivery to stem cells","volume":"7","author":"Kong","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bioadv.2024.214120_bb0540","first-page":"715","article-title":"Stat3 shRNA delivery with folate receptor-modified multi-functionalized graphene oxide particles for combined infrared radiation and gene therapy in hepatocellular carcinoma","volume":"34","author":"Chen","year":"2023","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.bioadv.2024.214120_bb0545","doi-asserted-by":"crossref","first-page":"7434","DOI":"10.3390\/ma16237434","article-title":"Poly(ethylene glycol)-engrafted graphene oxide for gene delivery and nucleic acid amplification","volume":"16","author":"Chauhan","year":"2023","journal-title":"Materials"},{"key":"10.1016\/j.bioadv.2024.214120_bb0550","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1021\/acs.molpharmaceut.8b00433","article-title":"Development of a Janus kinase inhibitor prodrug for the treatment of rheumatoid Arthritis","volume":"15","author":"Wei","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioadv.2024.214120_bb0555","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1021\/acs.molpharmaceut.7b00045","article-title":"Pharmacokinetic and biodistribution studies of HPMA copolymer conjugates in an aseptic implant loosening mouse model","volume":"14","author":"Wei","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioadv.2024.214120_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2023.121562","article-title":"A review of chitosan in gene therapy: developments and challenges","volume":"324","author":"Dong","year":"2024","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.bioadv.2024.214120_bb0565","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1021\/acs.biomac.7b01297","article-title":"siRNA delivery with chitosan: influence of chitosan molecular weight, degree of deacetylation, and amine to phosphate ratio on in vitro silencing efficiency, Hemocompatibility, biodistribution, and in vivo efficacy","volume":"19","author":"Alameh","year":"2018","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.bioadv.2024.214120_bb0570","article-title":"Delivery of siRNA using folate receptor-targeted pH-sensitive polymeric nanoparticles for rheumatoid arthritis therapy","volume":"20","author":"Sun","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.bioadv.2024.214120_bb0575","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.2147\/IJN.S180119","article-title":"pH-responsive hybrid nanoparticle with enhanced dissociation characteristic for siRNA delivery","volume":"13","author":"Shi","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bioadv.2024.214120_bb0580","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3390\/pharmaceutics14030533","article-title":"Lipid nanoparticles as a promising drug delivery carrier for topical ocular therapy\u2014an overview on recent advances","volume":"14","author":"Jacob","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioadv.2024.214120_bb0585","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3390\/nano9030474","article-title":"Application of solid lipid nanoparticles to improve the efficiency of anticancer drugs","volume":"9","author":"Bay\u00f3n-Cordero","year":"2019","journal-title":"Nanomaterials"},{"key":"10.1016\/j.bioadv.2024.214120_bb0590","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejps.2010.03.019","article-title":"Gene delivery by lipoplexes and polyplexes","volume":"40","author":"Tros de Ilarduya","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioadv.2024.214120_bb0595","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","article-title":"Toxicity of cationic lipids and cationic polymers in gene delivery","volume":"114","author":"Lv","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2024.214120_bb0600","doi-asserted-by":"crossref","first-page":"8266","DOI":"10.1166\/jnn.2012.6677","article-title":"PH-sensitive polyketal nanoparticles for drug delivery","volume":"12","author":"Wang","year":"2012","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0605","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nbt1402","article-title":"A combinatorial library of lipid-like materials for delivery of RNAi therapeutics","volume":"26","author":"Akinc","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0610","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202400679","article-title":"Targeted macrophage re-programming: Synergistic therapy with methotrexate and RELA siRNA folate-liposome in RAW264.7 cells and arthritic rats","volume":"13","author":"Nasra","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.bioadv.2024.214120_bb0615","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.3390\/pharmaceutics14081700","article-title":"New advances in biomedical application of polymeric micelles","volume":"14","author":"Figueiras","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioadv.2024.214120_bb0620","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202202400","article-title":"Advances in lipid-based codelivery systems for cancer and inflammatory diseases","volume":"12","author":"Jogdeo","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.bioadv.2024.214120_bb0625","first-page":"2520","article-title":"Nanomedicine-based combination of dexamethasone palmitate and MCL-1 siRNA for synergistic therapeutic efficacy against rheumatoid arthritis, drug Deliv","volume":"11","author":"Li","year":"2021","journal-title":"Transl. Res."},{"key":"10.1016\/j.bioadv.2024.214120_bb0630","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2217\/nnm.11.90","article-title":"Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model","volume":"6","author":"Scheinman","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.bioadv.2024.214120_bb0635","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biomaterials.2017.01.008","article-title":"Targeting NF-kB signaling with polymeric hybrid micelles that co-deliver siRNA and dexamethasone for arthritis therapy","volume":"122","author":"Wang","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioadv.2024.214120_bb0640","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpb.2019.06.009","article-title":"Lipidoid-polymer hybrid nanoparticles loaded with TNF siRNA suppress inflammation after intra-articular administration in a murine experimental arthritis model","volume":"142","author":"Jansen","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.bioadv.2024.214120_bb0645","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/mt.2008.220","article-title":"Chitosan\/siRNA nanoparticle-mediated TNF-\u03b1 knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model","volume":"17","author":"Howard","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioadv.2024.214120_bb0650","doi-asserted-by":"crossref","first-page":"23595","DOI":"10.1021\/acsami.8b06236","article-title":"Anti-inflammation and joint lubrication dual effects of a novel hyaluronic acid\/curcumin Nanomicelle improve the efficacy of rheumatoid arthritis therapy","volume":"10","author":"Fan","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bioadv.2024.214120_bb0655","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/jpet.108.150276","article-title":"Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate","volume":"329","author":"Ishihara","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioadv.2024.214120_bb0660","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2017.03.012","article-title":"Endogenous inspired biomineral-installed hyaluronan nanoparticles as pH-responsive carrier of methotrexate for rheumatoid arthritis","volume":"252","author":"Alam","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2024.214120_bb0665","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/nnm.13.217","article-title":"Polyethyleneimine-functionalized Iron oxide nanoparticles for systemic siRNA delivery in experimental arthritis","volume":"9","author":"Duan","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.bioadv.2024.214120_bb0670","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12951-018-0382-x","article-title":"Combination of NF-kB targeted siRNA and methotrexate in a hybrid nanocarrier towards the effective treatment in rheumatoid arthritis","volume":"16","author":"Duan","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0675","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1039\/C9BM01025D","article-title":"Nanoparticle-delivered siRNA targeting Bruton\u2019s tyrosine kinase for rheumatoid arthritis therapy","volume":"7","author":"Zhao","year":"2019","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.bioadv.2024.214120_bb0680","doi-asserted-by":"crossref","first-page":"8600","DOI":"10.1016\/j.biomaterials.2012.08.008","article-title":"The use of anti-COX2 siRNA coated onto PLGA nanoparticles loading dexamethasone in the treatment of rheumatoid arthritis","volume":"33","author":"Park","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioadv.2024.214120_bb0685","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3390\/pharmaceutics14010162","article-title":"Efficient treatment of rheumatoid arthritis by degradable LPCE Nano-conjugate-delivered p65 siRNA","volume":"14","author":"Chen","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioadv.2024.214120_bb0690","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mtcomm.2018.09.011","article-title":"Novel nano therapeutic materials for the effective treatment of rheumatoid arthritis-recent insights","volume":"17","author":"Janakiraman","year":"2018","journal-title":"Mater. Today Commun."},{"key":"10.1016\/j.bioadv.2024.214120_bb0695","article-title":"Systemic delivery of small interfering RNA targeting the Interleukin-2\/15 receptor \u03b2 chain prevents disease progression in experimental arthritis","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bioadv.2024.214120_bb0700","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.pmatsci.2019.03.003","article-title":"Dendrimer-entrapped gold nanoparticles as promising nanocarriers for anticancer therapeutics and imaging","volume":"103","author":"Kesharwani","year":"2019","journal-title":"Prog. Mater. Sci."},{"key":"10.1016\/j.bioadv.2024.214120_bb0705","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41596-020-00418-9","article-title":"Synthesis and use of an amphiphilic dendrimer for siRNA delivery into primary immune cells","volume":"16","author":"Chen","year":"2021","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bioadv.2024.214120_bb0710","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/630654","article-title":"Dendrimers as carriers for siRNA delivery and gene silencing: a review","volume":"2013","author":"Wu","year":"2013","journal-title":"Sci. World J."},{"key":"10.1016\/j.bioadv.2024.214120_bb0715","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.drudis.2016.12.007","article-title":"The use of nanoscaffolds and dendrimers in tissue engineering","volume":"22","author":"Gorain","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioadv.2024.214120_bb0720","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/B978-0-323-89953-6.00002-7","article-title":"Dendrimers: an effective drug delivery and therapeutic approach","author":"Gorain","year":"2023","journal-title":"Design and Applications of Theranostic Nanomedicines, Elsevier"},{"key":"10.1016\/j.bioadv.2024.214120_bb0725","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11095-011-0589-0","article-title":"Comparison of polymeric siRNA Nanocarriers in a murine LPS-activated macrophage cell line: gene silencing, toxicity and off-target gene expression","volume":"29","author":"Jensen","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioadv.2024.214120_bb0730","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202005661","article-title":"Targeted combination of Antioxidative and anti-inflammatory therapy of rheumatoid arthritis using multifunctional dendrimer-entrapped gold nanoparticles as a platform","volume":"16","author":"Li","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.bioadv.2024.214120_bb0735","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/ph6020223","article-title":"RNAi therapeutic platforms for lung diseases","volume":"6","author":"Fujita","year":"2013","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioadv.2024.214120_bb0740","first-page":"418","article-title":"siRNA for inflammatory diseases","volume":"10","author":"Ponnappa","year":"2009","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.bioadv.2024.214120_bb0745","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/ph6030287","article-title":"RNAi therapeutics in autoimmune disease","volume":"6","author":"Pauley","year":"2013","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioadv.2024.214120_bb0750","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.1016\/j.biomaterials.2013.04.060","article-title":"A review of the current status of siRNA nanomedicines in the treatment of cancer","volume":"34","author":"Resnier","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioadv.2024.214120_bb0755","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.addr.2009.04.018","article-title":"siRNA delivery systems for cancer treatment","volume":"61","author":"Oh","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioadv.2024.214120_bb0760","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2174\/1567201813666160816105408","article-title":"Overcoming the challenges of siRNA delivery: nanoparticle strategies","volume":"14","author":"Shajari","year":"2017","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.bioadv.2024.214120_bb0765","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1517\/14712598.2011.587801","article-title":"Nanocarriers: a tool to overcome biological barriers in siRNA delivery","volume":"11","author":"Kumari","year":"2011","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.bioadv.2024.214120_bb0770","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1208\/s12248-010-9210-4","article-title":"Delivery of siRNA therapeutics: barriers and carriers","volume":"12","author":"Wang","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.bioadv.2024.214120_bb0775","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1242\/jcs.066399","article-title":"Breaking down the barriers: siRNA delivery and endosome escape","volume":"123","author":"Dominska","year":"2010","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bioadv.2024.214120_bb0780","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/cbin.11841","article-title":"siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: a preliminary review","volume":"46","author":"Sargazi","year":"2022","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.bioadv.2024.214120_bb0785","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/CM9.0000000000000697","article-title":"Activity of fibroblast-like synoviocytes in rheumatoid arthritis was impaired by dickkopf-1 targeting siRNA","author":"Liu","year":"2020","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.bioadv.2024.214120_bb0790","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s12951-023-02147-z","article-title":"Engineering siRNA therapeutics: challenges and strategies","volume":"21","author":"Ali Zaidi","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0795","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/s12951-022-01667-4","article-title":"Cytoplasmic delivery of siRNA using human-derived membrane penetration-enhancing peptide","volume":"20","author":"Nakamura","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0800","doi-asserted-by":"crossref","DOI":"10.1155\/JBB\/2006\/63675","article-title":"Targeted delivery of siRNA","volume":"2006","author":"Oliveira","year":"2006","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bioadv.2024.214120_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106933","article-title":"Nanoparticle-facilitated delivery of BAFF-R siRNA for B cell intervention and rheumatoid arthritis therapy","volume":"88","author":"Wu","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0810","doi-asserted-by":"crossref","first-page":"10015","DOI":"10.1021\/acsnano.9b01892","article-title":"Intranasal delivery of mesenchymal stem cell derived exosomes loaded with phosphatase and Tensin homolog siRNA repairs complete spinal cord injury","volume":"13","author":"Guo","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.bioadv.2024.214120_bb0815","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.apsb.2017.11.011","article-title":"Improved method for synthesis of low molecular weight protamine\u2013siRNA conjugate","volume":"8","author":"Yu","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioadv.2024.214120_bb0820","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/ph13100294","article-title":"Overcoming barriers for siRNA therapeutics: from bench to bedside","volume":"13","author":"Sajid","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioadv.2024.214120_bb0825","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jconrel.2020.07.006","article-title":"Nanoparticle-siRNA: a potential strategy for rheumatoid arthritis therapy?","volume":"325","author":"Feng","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2024.214120_bb0830","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/oli.2008.0149","article-title":"Stability study of unmodified siRNA and relevance to clinical use","volume":"18","author":"Hickerson","year":"2008","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.bioadv.2024.214120_bb0835","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1021\/acs.molpharmaceut.0c00087","article-title":"Improved stability of siRNA-loaded lipid nanoparticles prepared with a PEG-Monoacyl fatty acid facilitates ligand-mediated siRNA delivery","volume":"17","author":"Sakurai","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioadv.2024.214120_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2021.462283","article-title":"Analytical techniques currently used in the pharmaceutical industry for the quality control of RNA-based therapeutics and ongoing developments","volume":"1651","author":"Demelenne","year":"2021","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.bioadv.2024.214120_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2021.462065","article-title":"Impurity profiling of siRNA by two-dimensional liquid chromatography-mass spectrometry with quinine carbamate anion-exchanger and ion-pair reversed-phase chromatography","volume":"1643","author":"Li","year":"2021","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.bioadv.2024.214120_bb0850","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1021\/ar300048p","article-title":"Lipid-based nanoparticles for siRNA delivery in Cancer therapy: paradigms and challenges","volume":"45","author":"Gomes-da-Silva","year":"2012","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.bioadv.2024.214120_bb0855","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jconrel.2007.04.018","article-title":"Polymer brush-stabilized polyplex for a siRNA carrier with long circulatory half-life","volume":"122","author":"Sato","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2024.214120_bb0860","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/nbt1339","article-title":"Mechanisms and optimization of in vivo delivery of lipophilic siRNAs","volume":"25","author":"Wolfrum","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0865","article-title":"Multifunctional polymeric micelle-based nucleic acid delivery: current advances and future perspectives","volume":"25","author":"Jarak","year":"2021","journal-title":"Appl. Mater. Today"},{"key":"10.1016\/j.bioadv.2024.214120_bb0870","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.progpolymsci.2016.09.008","article-title":"Recent advances in the design, development, and targeting mechanisms of polymeric micelles for delivery of siRNA in cancer therapy","volume":"64","author":"Amjad","year":"2017","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.bioadv.2024.214120_bb0875","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1016\/j.biomaterials.2011.01.059","article-title":"A single-monomer derived linear-like PEI-co-PEG for siRNA delivery and silencing","volume":"32","author":"Tsai","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioadv.2024.214120_bb0880","series-title":"Preparation of siRNA-Encapsulated PLGA Nanoparticles for Sustained Release of siRNA and Evaluation of Encapsulation Efficiency","first-page":"311","author":"Pantazis","year":"2012"},{"key":"10.1016\/j.bioadv.2024.214120_bb0885","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.598175","article-title":"Rationale and application of PEGylated lipid-based system for advanced target delivery of siRNA","volume":"11","author":"Ge","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0890","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.854859","article-title":"Synthesis and characterization of poly (\u03b2-amino Ester) and applied PEGylated and non-PEGylated poly (\u03b2-amino ester)\/plasmid DNA nanoparticles for efficient gene delivery","volume":"13","author":"Iqbal","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0895","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2174\/1389201017666160401145319","article-title":"Lipid-based siRNA delivery systems: challenges, promises and solutions along the Long journey","volume":"17","author":"Sarisozen","year":"2016","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0900","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1166\/jbn.2019.2663","article-title":"Changing the way of entrance: highly efficient transfer of mRNA and siRNA via Fusogenic Nano-carriers","volume":"15","author":"Hoffmann","year":"2019","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0905","series-title":"Cell-Penetrating Peptides Delivering siRNAs: An Overview","first-page":"329","author":"Falato","year":"2021"},{"key":"10.1016\/j.bioadv.2024.214120_bb0910","doi-asserted-by":"crossref","DOI":"10.1088\/1748-605X\/ac5415","article-title":"Aptamer-functionalized targeted siRNA delivery system for tumor immunotherapy","volume":"17","author":"Lv","year":"2022","journal-title":"Biomed. Mater."},{"key":"10.1016\/j.bioadv.2024.214120_bb0915","doi-asserted-by":"crossref","first-page":"45455","DOI":"10.1021\/acsami.9b16637","article-title":"Aptamer-based erythrocyte-derived mimic vesicles loaded with siRNA and doxorubicin for the targeted treatment of multidrug-resistant tumors","volume":"11","author":"Wang","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bioadv.2024.214120_bb0920","first-page":"1691","article-title":"A targeted <scp>siRNA<\/scp> -loaded <scp>PDL1<\/scp> -exosome and functional evaluation against lung cancer, Thorac","volume":"13","author":"Lin","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.bioadv.2024.214120_bb0925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/6971297","article-title":"Targeted delivery of siRNA therapeutics to malignant tumors","volume":"2017","author":"Leng","year":"2017","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.bioadv.2024.214120_bb0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.adcanc.2022.100047","article-title":"siRNA-based nanocarriers for targeted drug delivery to control breast cancer","volume":"4","author":"Ashique","year":"2022","journal-title":"Adv. Cancer Biol. - Metastasis"},{"key":"10.1016\/j.bioadv.2024.214120_bb0935","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1002\/ange.201308368","article-title":"Hypoxia-targeted siRNA delivery","volume":"126","author":"Perche","year":"2014","journal-title":"Angew. Chem."},{"key":"10.1016\/j.bioadv.2024.214120_bb0940","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12929-023-00981-9","article-title":"Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges","volume":"30","author":"Kang","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.bioadv.2024.214120_bb0945","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1002\/mco2.265","article-title":"Understanding and targeting resistance mechanisms in cancer","volume":"4","author":"Lei","year":"2023","journal-title":"MedComm (Beijing)"},{"key":"10.1016\/j.bioadv.2024.214120_bb0950","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/rheumatology\/keh333","article-title":"Corticosteroid resistance in rheumatoid arthritis: molecular and cellular perspectives","volume":"43","author":"Chikanza","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.bioadv.2024.214120_bb0955","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2020.08.002","article-title":"Drug-resistance in rheumatoid arthritis: the role of p53 gene mutations, ABC family transporters and personal factors","volume":"54","author":"Zhang","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100103","article-title":"New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy","volume":"3","author":"Kumar","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.bioadv.2024.214120_bb0965","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.trsl.2019.07.006","article-title":"Efficient nanocarriers of siRNA therapeutics for cancer treatment","volume":"214","author":"Subhan","year":"2019","journal-title":"Transl. Res."},{"key":"10.1016\/j.bioadv.2024.214120_bb0970","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12951-019-0444-8","article-title":"Efficient siRNA delivery and gene silencing using a lipopolypeptide hybrid vector mediated by a caveolae-mediated and temperature-dependent endocytic pathway","volume":"17","author":"Kasai","year":"2019","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bioadv.2024.214120_bb0975","doi-asserted-by":"crossref","first-page":"201","DOI":"10.7150\/thno.5743","article-title":"Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice","volume":"3","author":"Iversen","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/j.bioadv.2024.214120_bb0980","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.omtn.2017.08.013","article-title":"Polyethylenimine nanoparticle-mediated siRNA delivery to reduce \u03b1-Synuclein expression in a model of Parkinson\u2019s disease","volume":"9","author":"Helmschrodt","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bioadv.2024.214120_bb0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2019.110762","article-title":"Co-delivery of curcumin and Bcl-2 siRNA by PAMAM dendrimers for enhancement of the therapeutic efficacy in HeLa cancer cells","volume":"188","author":"Ghaffari","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.bioadv.2024.214120_bb0990","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/pharmaceutics15030735","article-title":"Recent advances in polymer-based nanomaterials for non-invasive Photothermal therapy of arthritis","volume":"15","author":"Tekade","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioadv.2024.214120_bb0995","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120947","article-title":"Folate receptor-targeting semiconducting polymer dots hybrid mesoporous silica nanoparticles against rheumatoid arthritis through synergistic photothermal therapy, photodynamic therapy, and chemotherapy","volume":"607","author":"Li","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bioadv.2024.214120_bb1000","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119851","article-title":"PRP-chitosan thermoresponsive hydrogel combined with black phosphorus nanosheets as injectable biomaterial for biotherapy and phototherapy treatment of rheumatoid arthritis","volume":"239","author":"Pan","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioadv.2024.214120_bb1005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2013.04.021","article-title":"Topical delivery of anti-TNF\u03b1 siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo","volume":"170","author":"Desai","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2024.214120_bb1010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.pdpdt.2017.06.003","article-title":"Sonodynamic therapy, a treatment developing from photodynamic therapy","volume":"19","author":"Rengeng","year":"2017","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"10.1016\/j.bioadv.2024.214120_bb1015","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2174\/1381612825666190123114107","article-title":"Photo- and Sono-dynamic therapy: a review of mechanisms and considerations for pharmacological agents used in therapy incorporating light and sound","volume":"25","author":"Yang","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bioadv.2024.214120_bb1020","series-title":"Therapeutic Ultrasound","first-page":"429","article-title":"Sonodynamic therapy: concept, mechanism and application to Cancer treatment","author":"McHale","year":"2016"},{"key":"10.1016\/j.bioadv.2024.214120_bb1025","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109978","article-title":"Photoacoustic\/ultrasound-guided gene silencing: multifunctional microbubbles for treating adjuvant-induced arthritis","volume":"117","author":"Zhao","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioadv.2024.214120_bb1030","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ultras.2013.10.021","article-title":"Sonoporation-mediated transduction of siRNA ameliorated experimental arthritis using 3MHz pulsed ultrasound","volume":"54","author":"Inoue","year":"2014","journal-title":"Ultrasonics"},{"key":"10.1016\/j.bioadv.2024.214120_bb1035","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1016\/j.ultrasmedbio.2023.08.006","article-title":"Role of ultrasonic microbubbles in treating rheumatoid arthritis: enhancing the efficacy of tocilizumab via contrast-enhanced ultrasound-monitored, ultrasound-targeted microbubble destruction","volume":"49","author":"Liu","year":"2023","journal-title":"Ultrasound Med. Biol."},{"key":"10.1016\/j.bioadv.2024.214120_bb1040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.13189\/nn.2016.040101","article-title":"Combination of Sonodynamic and photodynamic therapy against Cancer would be effective through using a regulated size of nanoparticles","volume":"4","author":"Miyoshi","year":"2016","journal-title":"Nanosci. Nanoeng."},{"key":"10.1016\/j.bioadv.2024.214120_bb1045","doi-asserted-by":"crossref","first-page":"S375","DOI":"10.33549\/physiolres.934374","article-title":"Effect of ClAlPcS2 photodynamic and sonodynamic therapy on hela cells","author":"Binder","year":"2019","journal-title":"Physiol. Res."},{"key":"10.1016\/j.bioadv.2024.214120_bb1050","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2147\/IJN.S120902","article-title":"Oxygen and indocyanine green loaded phase-transition nanoparticle-mediated photo-sonodynamic cytotoxic effects on rheumatoid arthritis fibroblast-like synoviocytes","volume":"12","author":"Tang","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bioadv.2024.214120_bb1055","doi-asserted-by":"crossref","unstructured":"C. McEwan, J. Owen, E. Stride, C. Fowley, H. Nesbitt, D. Cochrane, Constantin.C. Coussios, M. Borden, N. Nomikou, A.P. McHale, J.F. Callan, Oxygen carrying microbubbles for enhanced sonodynamic therapy of hypoxic tumours, J. Control. Release 203 (2015) 51\u201356. doi:https:\/\/doi.org\/10.1016\/j.jconrel.2015.02.004.","DOI":"10.1016\/j.jconrel.2015.02.004"}],"container-title":["Biomaterials Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772950824003637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772950824003637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T11:57:34Z","timestamp":1733745454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772950824003637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":211,"alternative-id":["S2772950824003637"],"URL":"https:\/\/doi.org\/10.1016\/j.bioadv.2024.214120","relation":{},"ISSN":["2772-9508"],"issn-type":[{"value":"2772-9508","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"siRNA-based nanotherapeutic approaches for targeted delivery in rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Biomaterials Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioadv.2024.214120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"214120"}}